The antibody drug Polivy, which targets CD79a, received NICE-recommended treatment for relapsed or incurable large B-cell lymphoma.

The National Institute for Health and Care Excellence (NICE) recommends combining Roche's antibody drug Polivy (polatuzumab vedotin) with rituximab and bendamustine to treat diffuse large B-cell lymphoma (DLBCL).
CD79b is an integral part of B-cell antigen receptors, has a high specificity, and has become an emerging target for the treatment of B-cell lymphoma after CD20.
: According to NICE, there are about 4,800 DBCL patients in the UK, of whom about 530 are eligible for Polivy combined treatment.
, the drug combination will be available to patients with relapses or non-responsiveness after first-line treatment and who are not suitable for stem cell transplants.
in clinical trials in DLBCL patients, the full remission rate for Polivy's combined Rituxan/Benzamostin was 40 percent, compared with 18 percent for the control group.
, the total survival of patients increased from 4.7 months to 11.8 months.
new treatment is good news for patients and clinicians, given the poor prognostic prognosticity of relapsed or resuscable DLBCL.
's drug combination was the first to show overall survival advantage in this class of patients.
.